- Conditions
- Esophageal Cancer, Malignant Neoplasm of Cardio-esophageal Junction of Stomach
- Interventions
- Azacitidine, Oxaliplatin, Epirubicin, Capecitabine
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 593
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obese Patients (BMI ≥ 30 kg/m²), Glucose Metabolism, Protein Metabolism
- Interventions
- Indispensable Amino Acid Oxidation, Stable Isotope Oral Glucose Tolerance Test
- Procedure
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 19 Years to 59 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Urbana, Illinois
- Conditions
- Adults Growth Hormone Deficiency.
- Interventions
- Pegvisomant, Regular insulin
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Multiple Myeloma
- Interventions
- Teclistamab, Mezigdomide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Major Depressive Disorder
- Interventions
- ActiveCBT, CalmCBT
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Ames, Iowa
- Conditions
- Diabetic Macular Edema
- Interventions
- Octreotide (drug), Placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
- Interventions
- Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Ovarian Carcinoma, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- OC-DC vaccine, Bevacizumab, cyclophosphamide 300 mg/m2/d for 3 days, fludarabine 30 mg/m2/d for 3 days, ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells
- Biological · Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Rib Fractures
- Interventions
- hydromorphone hydrochloride, Infusion catheter placement, bupivicaine 0.25%, bupivicaine 0.5%
- Drug · Procedure
- Lead sponsor
- Anthony Iacco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Breast Cancer, Lung Cancer, GI Cancer
- Interventions
- Pharmacy Intervention, Usual Care
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
- Interventions
- INKmune
- Biological
- Lead sponsor
- Inmune Bio, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Las Vegas, Nevada • Cincinnati, Ohio + 4 more
- Conditions
- Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
- Interventions
- aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22, aH5N6c on Day 22, aH5N8c on Day 202
- Biological
- Lead sponsor
- Seqirus
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more
- Conditions
- HIV Infections
- Interventions
- DNA CON-S env, IHV01, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Acute Promyelocytic Leukemia (M3), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- cytarabine, clofarabine, filgrastim, Ex-vivo expanded cord blood progenitor cell infusion, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- Nohla Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Covid19
- Interventions
- hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule)
- Biological · Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- El Segundo, California • Newport Beach, California
- Conditions
- Influenza, Vaccine
- Interventions
- cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS)
- Biological
- Lead sponsor
- PATH
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Cincinnati, Ohio
- Conditions
- Focus of the Study: Safety of XFB19
- Interventions
- XFB19, Placebo
- Drug
- Lead sponsor
- Xfibra, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Untreated Adult Acute Myeloid Leukemia, Myeloproliferative Neoplasm With 10% Blasts or Higher
- Interventions
- filgrastim, clofarabine, cytarabine
- Biological · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 3
- States / cities
- Duarte, California • Stanford, California • Seattle, Washington
- Conditions
- Depression
- Interventions
- PRIME 1.0, PRIME 2.0
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- HIV-1 Infection
- Interventions
- JS7 plasmid DNA and MVA62B vaccine
- Biological
- Lead sponsor
- GeoVax, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia
- Conditions
- Colorectal Carcinoma, Lynch Syndrome
- Interventions
- Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biospecimen Collection, Endoscopic Biopsy, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, Questionnaire Administration
- Biological · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Duarte, California • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Infertility, Diminished Ovarian Reserve, IVF
- Interventions
- Timing of injectable gonadotropins
- Procedure
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 20 Years to 45 Years · Female only
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Manhasset, New York
- Conditions
- Viral Diseases
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Autism Spectrum Disorder
- Interventions
- Treatment Package (for both simulation and procedure sessions
- Behavioral
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts